N.XT Portfolio

NuSera Biosystems

Investment Stage: Company

Funding Year: 2024

Faculty: Igor Efimov & John Rogers

Next-generation organ-conformal bioelectronics for diagnosing and treating heart diseases.

PreDx

Investment Stage: Company

Funding Year: 2024

Faculty: Thomas Meade

Novel class of bioresponsive contrast agents for monitoring physiological changes in live tissues via magnetic resonance imaging.

MFNS Tech

Investment Stage: Company

Funding Year: 2023

Faculty: Vinayak Dravid

Nanostructure coating for economic, efficient, and eco-friendly removal of oil and other contaminants from water.

CosmeTec

Investment Stage: Company

Funding Year: 2022

Faculty: Nathan Gianneschi

 A cleaner, safer, PPD-free hair dye based on synthetic melanin.

Syenex

Investment Stage: Company

Funding Year: 2022

Faculty: Josh Leonard

Breakthrough gene delivery technologies combining synthetic biology, engineering, and extracellular vesicles.

Opera Bioscience

Investment Stage: Company

Funding Year: 2022

Faculty: Danielle Tullman-Ercek

Cost-effective, microbial protein production platform that secretes high-purity, soluble, correctly folded recombinant proteins out of the cell in a single step.

Voice Savvy

Investment Stage: Technology

Funding Year: 2021

Faculty: Theresa Brancaccio & John Rogers

A mobile app for calculating vocal load and helping busy voice users monitor their vocal health.

History Adventures

Investment Stage: Technology

Funding Year: 2021

Faculty: Spencer Striker

An interactive digital platform that brings engaging history lessons to middle and high school students. In 2024, the startup History Adventures was spun out of this technology.

Cities Learn

Investment Stage: Technology

Funding Year: 2021

Faculty: Nichole Pinkard

A unified data system that tracks youth participation, achievement, and activity outside the classroom and aims to democratize access to afterschool activities. 

TunePad (now Eccentric Orbit)

Investment Stage: Technology

Funding Year: 2021

Faculty: Michael Horn

Online platform for creating music through the Python programming language with the goal of broadening participation in computing. In 2022, the startup Eccentric Orbit was spun out of this technology.

Stemloop

Investment Stage: Company

Funding Year: 2020

Faculty: Julius Lucks & Michael Jewett (former NU faculty)

Cell-free biosensors that enable rapid, low-cost solutions for the on-site detection of pathogens and chemical contaminants.

Azul 3D 

Investment Stage: Company

Funding Year: 2019

Faculty: Chad Mirkin

High-throughput 3D printing technologies that enable printing of large objects at unparalleled speeds from a wide range of consumer and industrial grade plastics.  

 Rhaeos

Investment Stage: Company

Funding Year: 2019

Faculty: John Rogers

Noninvasive, wireless, wearable thermal sensor for assessing the flow of cerebrospinal fluid in hydrocephalus patients and monitoring ventricular shunt function.

Yobee Care

Investment Stage: Company

Funding Year: 2018

Faculty: Ruchi Gupta

All-natural scalp treatment for reducing inflammation and restoring the balance of the scalp and skin microbiome.

Preora Healthcare (spinout: ASP Health)

Investment Stage: Company

Funding Year: 2017

Faculty: Vadim Backman

Platform that measures nanoscale cellular changes for the early detection and treatment of cancer. In 2020, ASP Health was spun out of Preora Healthcare to commercialize an innovative sample preparation technology for enhanced cancer diagnosis. 

Battery Technology (now Volexion)

Investment Stage: Technology

Funding Year: 2017

Faculty: Mark Hersam

Advanced graphene coating technology for lithium-ion cathode materials that boosts battery performance by 10x. In 2018, Volexion was spun out from this technology.

ALS Therapy (now AKAVA Therapeutics) 

Investment Stage: Technology

Funding Year: 2016

Faculty: Richard Silverman & Hande Ozdinler

First-in-class small molecule therapeutics that inhibit protein aggregation and improve the health of upper motor neurons in ALS other neurodegenerative diseases. In 2019, AKAVA Therapeutics was spun out from this technology.